Skip to main content

Respivant RVT1601-CC-04 SCENIC: Randomized double blind placebo controlled dose ranging efficacy and safety study with inhaled RVT-1601 for the treatment of persistent cough in patients with IPF

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Respivant Sciences, GmbH

Start Date

October 21, 2019

End Date

October 14, 2020
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Respivant Sciences, GmbH

Start Date

October 21, 2019

End Date

October 14, 2020